TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision's Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune DiseasesGlobeNewsWire • 01/09/24
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune DiseasesBusiness Wire • 01/09/24
TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/24
TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/27/23
Does TG Therapeutics (TGTX) Have the Potential to Rally 127.76% as Wall Street Analysts Expect?Zacks Investment Research • 11/06/23
TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) ConferenceGlobeNewsWire • 11/03/23
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/01/23
TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business UpdateGlobeNewsWire • 10/30/23
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual MeetingGlobeNewsWire • 10/12/23
TG Therapeutics: Racing Against Time While Their Differentiators Are Still RelevantSeeking Alpha • 10/03/23
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual MeetingGlobeNewsWire • 10/02/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against TG Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 09/27/23
TG Therapeutics to Participate in the 2023 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/22/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTXPRNewsWire • 09/13/23
TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/07/23